# US 2025/0084029 A1 · Lipids for use in lipid nanoparticle formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084029 A1
- Document ID: US20250084029A1
- Status: Published application
- Kind: A1
- Application number: 18/661,116
- Filed: 2024-05-10
- Published: 2025-03-13
- Earliest claimed: 2017-08-16
- Assignees: Acuitas Therapeutics, Inc.
- Applicants: Acuitas Therapeutics, Inc.
- Inventors: Xinyao Du
- Web page: https://patentgrep.com/patent/US20250084029A1

## CPC

- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

## Claims

### Claim 1

A compound having the following structure (I):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
L1 is —O(C═O)R1 or —(C═O)OR1;
L2 is —O(C═O)R2 or —(C═O)OR2;
G1 and G2 are each independently C4-C10 alkylene;
G3 is C2 or C3 alkylene,
R1 and R2 are each independently branched C6-C24 alkyl or branched C6-C24 alkenyl;
R3 is —N(R4)R5;
R4 is C1-C12 alkyl; and
R5 is substituted C1-C12 alkyl; and
wherein each alkyl, alkenyl and alkylene is unsubstituted unless otherwise specified.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The compound of claim 1, having one of the following structures (IB) or (IC):

### Claim at position 4

8-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein R1 and R2 are each, independently, branched C6-C24 alkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R1 and R2 each, independently have the following structure:
wherein:
R7a and R7b are, at each occurrence, independently H or C1-C12 alkyl; and
a is an integer from 2 to 12,
wherein R7a, R7b and a are each selected such that R1 and R2 are each independently branched and independently comprise from 6 to 20 carbon atoms.

### Claim 13 (depends on 12)

The compound of claim 12, wherein a is an integer from 8 to 12.

### Claim at position 8

14-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein R1 or R2, or both, independently has one of the following structures:

### Claim at position 10

19-21. (canceled)

### Claim 22 (depends on 1)

The compound of claim 1, wherein R4 is substituted or unsubstituted: methyl, ethyl, propyl, n-butyl, n-hexyl, n-octyl or n-nonyl.

### Claim at position 12

23-24. (canceled)

### Claim 25 (depends on 1)

The compound of claim 1, wherein R5 is substituted: methyl, ethyl, propyl, n-butyl, n-hexyl, n-octyl or n-nonyl.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R5 is substituted ethyl or substituted propyl.

### Claim 27 (depends on 25)

The compound of claim 25, wherein R4 is methyl.

### Claim 28 (depends on 25)

The compound of claim 25, wherein R5 is substituted with hydroxyl.

### Claim 29 (depends on 25)

The compound of claim 25, wherein R5 is substituted with one or more substituents selected from the group consisting of —ORg, —NRgC(═O)Rh,
—C(═O)NRgRh, —C(═O)Rh, —OC(═O)Rh, —C(═O)ORh and —ORiOH, wherein:
Rg is, at each occurrence independently H or C1-C6 alkyl;
Rh is at each occurrence independently C1-C6 alkyl; and
Ri is, at each occurrence independently C1-C6 alkylene.

### Claim 30 (depends on 1)

The compound of claim 1, wherein R3 has one of the following structures:

### Claim 31

A compound having one of the following structures:

### Claim 32 (depends on 1)

A composition comprising the compound of claim 1 and a therapeutic agent.

### Claim at position 21

33-47. (canceled)

### Claim 48 (depends on 1)

A lipid nanoparticle comprising the compound of claim 1.

### Claim 49 (depends on 48)

A pharmaceutical composition comprising the lipid nanoparticle of claim 48 and a pharmaceutically acceptable diluent or excipient.

### Claim 50 (depends on 48)

A method for inducing expression of a protein in a subject, comprising administering to the subject the lipid nanoparticle of claim 48, wherein the lipid nanoparticle comprises an mRNA encoding the protein.

### Claim 51

A lipid nanoparticle comprising a compound having the following structure (I):
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
L1 is —O(C═O)R1, —(C═O)OR1, —C(═O)R1, —OR1, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc or —NRaC(═O)OR1;
L2 is —O(C═O)R2, —(C═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf;
—NRdC(═O)OR2 or a direct bond to R2;
G1 and G2 are each independently C2-C12 alkylene or C2-C12 alkenylene;
G3 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
Ra, Rb, Rd and Re are each independently H or C1-C12 alkyl or C1-C12 alkenyl;
Rc and Rf are each independently C1-C12 alkyl or C2-C12 alkenyl;
R1 and R2 are each independently branched C6-C24 alkyl or branched C6-C24 alkenyl;
R3 is —N(R4)R5;
R4 is C1-C12 alkyl;
R5 is substituted C1-C12 alkyl; and
x is 0, 1 or 2, and
wherein each alkyl, alkenyl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, aryl and aralkyl is independently substituted or unsubstituted unless otherwise specified.

### Claim 52 (depends on 51)

The lipid nanoparticle of claim 51, further comprising an mRNA encoding a protein.
